Adverse effects | The number of study | Pazopanib group (event/total) | Sunitinib group (event/total) | RR (95% CI) | P value | Heterogeneity | |
---|---|---|---|---|---|---|---|
I2 (%) | P value | ||||||
Diarrhea | 3 | 51/660 | 43/691 | 1.19 [0.81–1.74] | 0.38 | 0 | 0.42 |
Fatigue | 3 | 60/660 | 102/691 | 0.59 [0.44–0.80] | 0.0006 | 0 | 0.49 |
Hypertension | 2 | 83/626 | 93/648 | 0.43 [0.05–3.53] | 0.43 | 78 | 0.03 |
Nausea/Vomiting | 3 | 25/660 | 29/691 | 0.87 [0.52–1.46] | 0.61 | 0 | 0.61 |
Leukopenia | 2 | 6/626 | 39/648 | 0.26 [0.03–2.55] | 0.25 | 84 | 0.01 |
Thrombocytopenia | 2 | 20/626 | 131/648 | 0.16 [0.10–0.25] | < 0.00001 | 0 | 0.37 |
Neutropenia | 2 | 28/626 | 127/648 | 0.23 [0.15–0.34] | <  0.00001 | 0 | 0.97 |
Increased creatinine | 2 | 4/626 | 8/648 | 0.49 [0.15–1.63] | 0.25 | NA | NA |
Increased AST | 2 | 71/626 | 16/648 | 4.46 [2.62–7.58] | < 0.00001 | 0 | 0.69 |
Increased ALT | 2 | 99/626 | 23/648 | 4.34 [2.79–6.75] | < 0.00001 | 0 | 0.40 |